Tumor Biology

, Volume 34, Issue 3, pp 1569–1578

Prognostic value of bcl-2 expression among women with breast cancer in Libya

  • Eramah Ermiah
  • Abdelbaset Buhmeida
  • Ben Romdhane Khaled
  • Fathi Abdalla
  • Nada Salem
  • Seppo Pyrhönen
  • Yrjö Collan
Research Article

DOI: 10.1007/s13277-013-0687-1

Cite this article as:
Ermiah, E., Buhmeida, A., Khaled, B.R. et al. Tumor Biol. (2013) 34: 1569. doi:10.1007/s13277-013-0687-1

Abstract

We studied the association of the immunohistochemical bcl-2 expression in Libyan breast cancer with clinicopathological variables and patient outcome. Histological samples from 170 previously untreated primary Libyan breast carcinoma patients were examined. In immunohistochemistry, the NCL-l-bcl-2-486 monoclonal antibody was used. Positive expression of bcl-2 was found in 106 patients (62.4 %). The bcl-2 expression was significantly associated with estrogen receptor (p < 0.0001) and progesterone receptor positive tumors (p = 0.002), small tumor size (p < 0.0001), low tumor grade (p < 0.0001), negative axillary lymph nodes (p < 0.0001), early stages (p = 0.001), and low risk of metastasis (p < 0.0001). Positive expression was also associated with older patients (>50 years; p = 0.04). Histological subtypes and family history of breast cancer did not have significant relationship with bcl-2. Patients with positive expression of bcl-2 had lower recurrence rate than bcl-2-negative patients and better survival after median follow-up of 47 months. Patients with high bcl-2 staining were associated with the best survival. The role of bcl-2 as an independent predictor of disease-specific survival was assessed in a multivariate survival (Cox) analysis, including age, hormonal status, recurrence, histological grade, and clinical stage variables. Bcl-2 (p < 0.0001) and clinical stage (p = 0.016) were independent predicators of disease-specific survival. For analysis of disease-free survival, the same variables were entered to the model and only bcl-2 proved to be an independent predictor (p = 0.002). Patients with positive expression of bcl-2 were associated with low grade of malignancy, with lower recurrence rate, with lower rate of death, and with longer survival time. Bcl-2 is an independent predictor of breast cancer outcome, and it provides useful prognostic information in Libyan breast cancer. Thus, it could be used with classical clinicopathological factors to improve patient selection for therapy.

Keywords

bcl-2 expressionLibyan female breast cancerPrognosis

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Eramah Ermiah
    • 1
    • 2
  • Abdelbaset Buhmeida
    • 3
  • Ben Romdhane Khaled
    • 4
  • Fathi Abdalla
    • 5
  • Nada Salem
    • 6
  • Seppo Pyrhönen
    • 1
  • Yrjö Collan
    • 7
  1. 1.Department of OncologyUniversity of Turku and Turku University HospitalTurkuFinland
  2. 2.Department of OncologyNational Cancer InstituteSabrathaLibya
  3. 3.Center of Excellence in Genomic Medicine ResearchKing Abdul-Aziz UniversityJeddahSaudi Arabia
  4. 4.Department of PathologySalah Azaiz Cancer InstituteTunisTunisia
  5. 5.Department of PathologyMisurata Cancer InstituteMisurataLibya
  6. 6.Department of BiochemistryKing Abdul-Aziz UniversityJeddahSaudi Arabia
  7. 7.Department of PathologyUniversity of Turku and Turku University HospitalTurkuFinland